Search results for "ejection fraction"

showing 10 items of 378 documents

Obesity and Outcomes in COVID-19: When an Epidemic and Pandemic Collide.

2020

Obesity has reached epidemic proportions in the United States and in much of the westernized world, contributing to considerable morbidity. Several of these obesity-related morbidities are associated with greater risk for death with coronavirus disease 2019 (COVID-19). Severe acute respiratory syndrome coronavirus 2 penetrates human cells through direct binding with angiotensin-converting enzyme 2 receptors on the cell surface. Angiotensin-converting enzyme 2 expression in adipose tissue is higher than that in lung tissue, which means that adipose tissue may be vulnerable to COVID-19 infection. Obese patients also have worse outcomes with COVID-19 infection, including respiratory failure, n…

BMI body mass indexmedicine.medical_treatmentAdipose tissue030204 cardiovascular system & hematologyCHD coronary heart diseaseHF heart failureUS United States0302 clinical medicineRAAS renin-angiotensin-aldosterone systemPandemicMedicine030212 general & internal medicineCDC Centers for Disease Control and PreventionCOVID-19 coronavirus disease 2019TNF tumor necrosis factorHFpEF HF with preserved ejection fractionCV cardiovascularGeneral MedicinePrognosisICU intensive care unitPA physical activityMetS metabolic syndromePAH pulmonary arterial hypertensionCoronavirus Infectionsmedicine.medical_specialtyAF atrial fibrillationACE angiotensin-converting enzymePneumonia ViralCVD cardiovascular diseaseSARS-CoV-2 severe acute respiratory syndrome coronavirus 2ArticleSeverity03 medical and health sciencesBetacoronavirusInternal medicineIPF idiopathic pulmonary fibrosisHumansObesityMortalityHTN hypertension or hypertensivePandemicsMechanical ventilationAng II angiotensin IIbusiness.industrySARS-CoV-2CKD chronic kidney diseaseCOVID-19T2DM type 2 diabetes mellitusmedicine.diseaseAngiotensin IIObesityIL interleukinPneumoniaRespiratory failureMetabolic syndromebusinessSNS sympathetic nervousMayo Clinic proceedings
researchProduct

An Easy Assessment of Frailty at Baseline Independently Predicts Prognosis in Very Elderly Patients With Acute Coronary Syndromes.

2017

Background: Information about the impact of frailty in patients with acute coronary syndromes (ACS) is scarce. No study has assessed the prognostic impact of frailty as measured by the FRAIL scale in very elderly patients with ACS. Methods: The prospective multicenter LONGEVO-SCA registry included unselected patients with ACS aged 80 years or older. A comprehensive geriatric assessment was performed during hospitalization, including frailty assessment by the FRAIL scale. The primary endpoint was mortality at 6 months. Results: A total of 532 patients were included. Mean age was 84.3 years, 61.7% male. Most patients had positive troponin levels (84%) and high GRACE risk score values (mean 16…

Background informationMalemedicine.medical_specialtyTime FactorsFrail ElderlyEnfermedad cardiovascularAncianoComorbidityKaplan-Meier Estimate030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineInternal medicineCause of DeathClinical endpointPrevalenceMedicineHumansIn patient030212 general & internal medicineProspective StudiesRegistriesAcute Coronary SyndromeGeneral NursingProportional Hazards ModelsAged 80 and overFramingham Risk ScoreEjection fractionbiologyFrailtybusiness.industryHealth PolicyMortality rateGeriatric assessmentGeneral MedicinePrognosisTroponinSurvival AnalysisSpainbiology.proteinCardiopatía coronariaFemaleGeriatrics and GerontologybusinessAncianosJournal of the American Medical Directors Association
researchProduct

Postnatal Overfeeding Causes Early Shifts in Gene Expression in the Heart and Long-Term Alterations in Cardiometabolic and Oxidative Parameters

2013

International audience; Background: Postnatal overfeeding (OF) in rodents induces a permanent moderate increase in body weight in adulthood. However, the repercussions of postnatal OF on cardiac gene expression, cardiac metabolism and nitro-oxidative stress are less well known. Methodology/Principal Findings: Immediately after birth, litters of C57BL/6 mice were either maintained at 10 (normal-fed group, NF), or reduced to 3 in order to induce OF. At weaning, mice of both groups received a standard diet. The cardiac gene expression profile was determined at weaning and cardiac metabolism and oxidative stress were assessed at 7 months. The cardiac expression of several genes, including membe…

Blood GlucoseAnatomy and PhysiologyTime FactorsMouseMicroarrays[SDV]Life Sciences [q-bio]Myocardial InfarctionGene Expressionlcsh:Medicine030204 cardiovascular system & hematologyCardiovascularmedicine.disease_causeCardiovascular SystemMiceOvernutrition0302 clinical medicineBlood plasmaInsulinlcsh:Science2. Zero hungerRegulation of gene expression0303 health sciencesMultidisciplinaryEjection fractionVentricular RemodelingHeartAnimal ModelsReactive Nitrogen Species[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemApelin[SDV] Life Sciences [q-bio]Body CompositionMedicineFemaleDisease SusceptibilityOxidation-ReductionResearch ArticlePhysiogenomicsmedicine.medical_specialtyDiastoleEndocrine SystemMyocardial Reperfusion InjuryBiology03 medical and health sciencesModel Organisms[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicinemedicineAnimalsWeaningVentricular remodelingBiology030304 developmental biologyEndocrine Physiology[ SDV ] Life Sciences [q-bio]Gene Expression ProfilingMyocardiumBody Weightlcsh:RComputational Biologymedicine.diseaseOxidative StressEndocrinologyGene Expression Regulationlcsh:QOxidative stress
researchProduct

Early subclinical ventricular dysfunction in patients with insulin resistance

2014

AIMS: The aim of our study was to evaluate the relationship between insulin resistance and the detection of precocious echocardiographic signs of heart failure in patients with cardiovascular risk factors. METHODS: We enrolled 34 consecutive patients with cardiovascular risk factors. All patients underwent coronary angiography, echocardiography, and laboratory tests. Exclusion criteria were diabetes (fasting glucose greater than 126 mg/dl or treatment with insulin or oral hypoglycemic agents), coronary artery disease, creatinine above 1.5 mg/dl, left-ventricular hypertrophy, valvular heart disease, ejection fraction below 50%, atrial fibrillation, or other severe arrhythmia. The presence of…

Blood GlucoseMalemedicine.medical_specialtymedicine.medical_treatmentDiastolePilot ProjectsRisk AssessmentVentricular Function LeftCoronary artery diseaseVentricular Dysfunction LeftInsulin resistancePredictive Value of TestsRisk FactorsDiabetes mellitusInternal medicinemedicineHumansInsulinVentricular dysfunctionAgedUltrasonographyHeart FailureEjection fractionbusiness.industryInsulinAtrial fibrillationGeneral MedicineMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareLogistic ModelsHeart failureAsymptomatic DiseasesMultivariate AnalysisCardiologyFemaleInsulin ResistanceCardiology and Cardiovascular MedicinebusinessBiomarkersJournal of Cardiovascular Medicine
researchProduct

Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozinvsplacebo or empagliflozin in patients with type 2 diabetes and heart f…

2020

Aims Explore the efficacy, safety and tolerability of the dual sodium-glucose cotransporter (SGLT) 1 and 2 inhibitor, licogliflozin in patients with type-2 diabetes mellitus (T2DM) and heart failure. Methods This multicentre, parallel-group phase IIA study randomized 125 patients with T2DM and heart failure (New York Heart Association II-IV; plasma N-terminal pro b-type natriuretic peptide [NT-proBNP] >300 pg/mL) to licogliflozin (2.5 mg, 10 mg, 50 mg) taken at bedtime, empagliflozin (25 mg) or placebo (44 patients completed the study). The primary endpoint was change from baseline in NT-proBNP after 12 weeks. Secondary endpoints included change from baseline in glycated haemoglobin, fas…

Blood Glucosemedicine.medical_specialtyUrologyheart failureType 2 diabetesPlacebo030226 pharmacology & pharmacyBedtimeAnhydridesSGLT2 INHIBITORS03 medical and health sciencespharmacotherapy0302 clinical medicineDouble-Blind MethodGlucosidesDiabetes mellitusmedicineEmpagliflozinHumansHypoglycemic AgentsSorbitolPharmacology (medical)030212 general & internal medicineCOTRANSPORTER 2 INHIBITORSBenzhydryl CompoundsPharmacologyGlycated HemoglobinOUTCOMESbusiness.industrySodiumbiomarkersOriginal Articlesmedicine.diseaseEFFICACYBlood pressureGlucoseTreatment OutcomeTolerabilityDiabetes Mellitus Type 2PRESERVED EJECTION FRACTIONHeart failureSAFETYOriginal Articlebiomarkers heart failure pharmacotherapy type 2 diabetestype 2 diabetesbusinessBritish Journal of Clinical Pharmacology
researchProduct

Phenotype/Genotype Relationship in Left Ventricular Noncompaction: Ion Channel Gene Mutations Are Associated With Preserved Left Ventricular Systolic…

2021

International audience; Background: Few data exist concerning genotype-phenotype relationships in left ventricular noncompaction (LVNC).Methods and results: From a multicenter French Registry, we report the genetic and clinical spectrum of 95 patients with LVNC, and their genotype-phenotype relationship. Among the 95 LVNC, 45 had at least 1 mutation, including 14 cases of mutation in ion channel genes. In a complementary analysis including 16 additional patients with ion channel gene mutations, for a total of 30 patients with ion channel gene mutation, we found that those patients had higher median LV ejection fraction (60% vs 40%; P < .001) and more biventricular noncompaction (53.1% vs 18…

Bradycardiamedicine.medical_specialtyLeft ventricular noncompactionphenotypegenotypeGenetic counselingregistry030204 cardiovascular system & hematologyGene mutationmedicine.disease_cause03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInternal medicineGenotypemedicineechocardiography[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology030212 general & internal medicineComputingMilieux_MISCELLANEOUSMutation[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseasesEjection fractionbusiness.industryPhenotype[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology3. Good health[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyCardiologyLeft ventricular noncompactionmedicine.symptomCardiology and Cardiovascular Medicinebusiness
researchProduct

Determinants of procalcitonin concentration in acute heart failure.

2014

Age, years 73.1 ± 10.4 Male, n (%) 133 (51.0) Hypertension, n (%) 212 (81.2) Diabetes mellitus, n (%) 126 (49.4) Previous smoker, n (%) 104 (28.2) Ischemic etiology, n (%) 92 (35.3) Peripheral oedema, n (%) 187 (71.7) Previous admission for AHF, n (%) 95 (36.4) Prior use of beta-blockers, n (%) 111 (42.5) Prior use of loop diuretics, n (%) 175 (67.0) Prior use of ACEI/ARB, n (%) 134 (51.3) Heart rate, beats/min 97 ± 28 SBP, mm Hg 148 ± 34 DBP, mm Hg 81 ± 19 Atrial fibrillation, n (%) 119 (45.6) Hemoglobin, g/dl 12.1 ± 2.0 Serum creatinine, mg/dl 1.23 ± 0.57 Urea, mg/dl 60.5 ± 30.1 Sodium, mEq/l 137.8 ± 4.7 NT-proBNP, pg/ml 4813 (6011) Leukocyte count, 10 cells/l 9286 ± 3468 Relative lymphoc…

CalcitoninMalemedicine.medical_specialtyCalcitonin Gene-Related PeptideFibrinogenGastroenterologyProcalcitoninCohort Studieschemistry.chemical_compoundInternal medicineHeart ratemedicineHumansProtein PrecursorsHeart FailureCreatinineEjection fractionbusiness.industryMiddle Agedmedicine.diseasechemistryHeart failureAcute DiseaseUreaFemaleHemoglobinCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugInternational journal of cardiology
researchProduct

Tricuspid valve repair with the Cardioband system: two-year outcomes of the multicentre, prospective TRI-REPAIR study

2021

AIMS: Tricuspid regurgitation (TR) is associated with high morbidity and mortality rates with limited treatment options. We report one- and two-year outcomes of the Cardioband tricuspid valve reconstruction system in the treatment of ≥moderate functional TR in the TRI-REPAIR study. METHODS AND RESULTS: Thirty patients were enrolled in this single-arm, multicentre, prospective study. Patients were evaluated as having ≥moderate, symptomatic functional TR and deemed inoperable due to unacceptable surgical risk. Clinical, functional, and echocardiographic data were prospectively collected up to two years (mean duration 604±227 days). At baseline, 83% were in NYHA Class III-IV, and the mean LVEF…

Cardiac Catheterizationmedicine.medical_specialtyTime Factors030204 cardiovascular system & hematologySeverity of Illness Index03 medical and health sciences0302 clinical medicineQuality of lifeClinical ResearchInternal medicineHumansMedicineIn patientProspective Studies030212 general & internal medicineTRICUSPID VALVE REPAIRProspective cohort studyRetrospective StudiesHeart Valve Prosthesis ImplantationEjection fractionTricuspid valvebusiness.industryWalk distanceMortality rateTricuspid Valve InsufficiencyTreatment Outcomemedicine.anatomical_structureCardiologyTricuspid ValveCardiology and Cardiovascular MedicinebusinessEuroIntervention
researchProduct

Prognostic significance of central venous-to-arterial carbon dioxide difference during the first 24 hours of septic shock in patients with and withou…

2017

IF 6.238; International audience; Objective: To investigate the prognostic significance of central venous-to-arterial carbon dioxide difference (cv-art CO2 gap) during septic shock in patients with and without impaired cardiac function.Methods: We performed a prospective cohort study in 10 French intensive care units. Patients suffering from septic shock were assigned to the impaired cardiac function group (‘cardiac group’, n=123) if they had atrial fibrillation (AF) and/or left ventricular ejection fraction (LVEF) 0.9 kPa at 12 h had a higher risk of day 28 mortality (hazard ratio=3.18; P=0.0049). Among the 59 patients in the cardiac group with mean arterial pressure (MAP) ≥65 mm Hg, centr…

Cardiac function curveAdultMalemedicine.medical_specialtyMean arterial pressureAdolescentCentral Venous Pressurecentral venous-arterial CO2 difference030204 cardiovascular system & hematologyVentricular Function Left03 medical and health sciencesYoung Adult0302 clinical medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyInternal medicineIntensive caremedicineHumansArterial PressureProspective StudiesAgedEjection fractionbusiness.industrySeptic shockCentral venous pressure030208 emergency & critical care medicineCarbon DioxideMiddle Agedmedicine.diseasePrognosisShock Septic3. Good healthSurgeryAnesthesiology and Pain MedicineBlood pressureblood gas analysisCardiologyArterial bloodseptic shockFemalebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Epicardial Fat, Cardiac Geometry and Cardiac Function in Patients with Nonalcoholic Fatty Liver Disease: Association with the Severity of Liver Disea…

2015

Background & Aims Non-alcoholic fatty liver disease (NAFLD) has been associated with increased cardiovascular risk, including coronary artery disease and cardiac dysfunction. In addition, recent evidence highlighted the possible role of epicardial fat as a new cardiometabolic risk factor. We tested the correlation between epicardial fat, alterations in cardiac geometry and function, and severity of liver damage, in patients with biopsy-proven NAFLD. Methods The anthropometric, biochemical and metabolic features were recorded in 147 consecutive biopsy-proven NAFLD cases (Kleiner score). Epicardial fat thickness was measured by echocardiography. Results Epicardial fat was higher in patients w…

Cardiac function curveAdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaStatistics as TopicDiastoleEPICARDIAL FATSettore MED/08 - Anatomia PatologicaSeverity of Illness IndexCoronary artery diseaseLiver diseaseFibrosisNon-alcoholic Fatty Liver DiseaseRisk FactorsNASH; NAFLD; EPICARDIAL FAT; CARDIAC DYSFUNCTION;Internal medicineNAFLDmedicineHumansSettore MED/12 - GastroenterologiaEjection fractionHepatologybusiness.industryFatty liverNASHHeartMiddle Agedmedicine.diseaseEndocrinologyLiverCardiovascular DiseasesEchocardiographyCardiologyFemaleSteatohepatitisbusinessPericardiumCARDIAC DYSFUNCTION
researchProduct